기업 프로필 · Healthcare

Merck KGaA

MRK · XETRA
거래소
XETRA
국가 / 지역
Germany
직원 수
59,077
웹사이트
www.emdgroup.com
현재가
136.45
실시간 · 2026년 6월 11일
적정 매수가
≤ €95
안전마진 진입가
베일리 성장 점수
49/100
다소 약함
내재가치 · 3단계 구간 현재가 €136.45 실시간 · 적정 내재가치 구간 내

종합 밸류에이션 구간 · 보수적 €90–€95 / 적정 €119–€161 / 낙관적 €180–€195. €136.45 기준, 적정 내재가치 구간 내.

보고서 발행 시 €133.05(2026년 6월 19일)

Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA is a subsidiary of E. Merck KG.

시가총액€574.12억
매출 (TTM)€209.56억
EBITDA€56.74억
순이익률12.08%
ROE8.53%
PER (TTM)22.65
선행 PER19.34
PEG2.61
EPS€5.83
배당수익률1.66%
52주 범위€98.72 – €140.25

데이터 제공: EODHD, 보고 통화 기준 표시. 참고용일 뿐 투자 자문이 아닙니다.

연혁

준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.

업계 내 위치

준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.